Lanier S M, Graham R M, Hess H J, Grodski A, Repaske M G, Nunnari J M, Limbird L E, Homcy C J
Proc Natl Acad Sci U S A. 1986 Dec;83(24):9358-62. doi: 10.1073/pnas.83.24.9358.
A functionalized derivative of the alpha 2-selective antagonist rauwolscine formed the basis for a photoaffinity adduct that has allowed identification of the hormone-binding subunit of the brain alpha 2-adrenergic receptor protein. Rauwolscine carboxylate underwent reaction with 4-N-t-butyloxycarbonyl-aminoaniline, leading to the synthesis of rauwolscine 4-aminophenyl carboxamide (Rau-AmPC). Rau-AmPC was radioiodinated and converted to the arylazide derivative, 17 alpha-hydroxy-20 alpha-yohimban-16 beta-[N-(4-azido-3-[125I]iodo)phenyl] carboxamide (125I-Rau-AzPC), via a diazonium salt intermediate. The characterization of 125I-Rau-AzPC as a photolabile probe employed alpha 2-adrenergic receptors, which were first solubilized from porcine brain membranes and partially purified by affinity chromatography utilizing a yohimbine-agarose affinity matrix. In the partially purified receptor preparation incubated with 125I-Rau-AzPC, photolysis resulted in covalent labeling of a major (Mr, 62,000) peptide as determined by NaDodSO4/PAGE and autoradiography. Labeling of this peptide was inhibited by the alpha 2-selective antagonist, yohimbine, and the non-subtype-selective alpha-antagonist, phentolamine, but not by the alpha 1-antagonist, prazosin, or the beta-receptor antagonist, (-)-alprenolol. The alpha-adrenergic agonist epinephrine also inhibited labeling in a stereoselective manner. These data indicate that the photolabeled Mr 62,000 peptide is the hormone-binding subunit of the alpha 2-adrenergic receptor protein. The availability of this radioiodinated photoaffinity probe for the alpha 2-adrenergic receptor should facilitate further structural and biophysical characterization of the receptor protein.
α₂选择性拮抗剂萝芙辛的一种功能化衍生物构成了一种光亲和加合物的基础,该加合物使得能够鉴定脑α₂肾上腺素能受体蛋白的激素结合亚基。萝芙辛羧酸盐与4-N-叔丁氧羰基-氨基苯胺反应,从而合成了萝芙辛4-氨基苯基羧酰胺(Rau-AmPC)。Rau-AmPC经放射性碘化并通过重氮盐中间体转化为芳基叠氮化物衍生物,即17α-羟基-20α-育亨宾-16β-[N-(4-叠氮基-3-[¹²⁵I]碘)phenyl]羧酰胺(¹²⁵I-Rau-AzPC)。¹²⁵I-Rau-AzPC作为一种光不稳定探针的表征使用了α₂肾上腺素能受体,该受体首先从猪脑膜中溶解出来,并利用育亨宾-琼脂糖亲和基质通过亲和色谱法进行部分纯化。在用¹²⁵I-Rau-AzPC孵育的部分纯化受体制剂中,光解导致通过NaDodSO₄/PAGE和放射自显影确定的一种主要(Mr,62,000)肽的共价标记。α₂选择性拮抗剂育亨宾和非亚型选择性α拮抗剂酚妥拉明可抑制该肽的标记,但α₁拮抗剂哌唑嗪或β受体拮抗剂(-)-阿普洛尔则不能。α肾上腺素能激动剂肾上腺素也以立体选择性方式抑制标记。这些数据表明,光标记的Mr 62,000肽是α₂肾上腺素能受体蛋白的激素结合亚基。这种用于α₂肾上腺素能受体的放射性碘化光亲和探针的可用性应有助于受体蛋白的进一步结构和生物物理表征。